Collegium Pharma (COLL) Misses Q1 EPS by $1.29

Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.39), $1.29 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $78.88 million.

GUIDANCE:

Collegium Pharma sees FY2022 revenue of $450-465 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• UBS says bull market has further to run